A important advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://bookmarksystem.com/story21172174/significant-introduction-tirzepatide-strength-for-diabetes-management